Cutaquig

Peak

immunoglobulin g

BLASUBCUTANEOUSSOLUTION
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10

Mechanism of Action

(IgG) antibodies against a wide variety of bacterial and viral agents. It has a distribution of immune globulin subclasses closely proportional to that in native human plasma. The mechanism of action in primary humoral immunodeficiency (PI) has not been fully elucidated; however adequate doses may…

Pharmacologic Class:

Antigen Neutralization

Clinical Trials (5)

NCT07025577Phase 1Completed

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

Started Jun 2025
82 enrolled
Healthy Participants
NCT04354129N/AActive Not Recruiting

Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.

Started Apr 2023
36 enrolled
Primary Immune Deficiency DisorderSecondary Immune Deficiency
NCT04918147Phase 2Terminated

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Started Oct 2021
8 enrolled
IgG4 Related DiseaseIgG4-RD
NCT03677557Phase 4Unknown

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Started Sep 2018
30 enrolled
Primary Immunodeficiency DiseaseSecondary Immunodeficiency
NCT03369301N/ACompleted

The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

Started Sep 2017
102 enrolled
Secondary Immune Deficiency